1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Meloxicam |
| brand | String | Mobic, Vivlodex (lower-dose capsules), Anjeso (IV) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID • preferential COX-2)]] • [[:Category:Analgesics|Analgesic]] |
| mechanism | String | '"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'. |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | 7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg |
| preparations | String | Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) |
| fda_max | String | 15 mg/day (oral); 30 mg IV once daily (Anjeso) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • intravenous |
| onset | String | Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks |
| duration | String | 24 hours (once-daily dosing supported by long half-life) |
| halflife | String | 15-20 hours'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~89% (oral)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
